Task Specific Training for Advanced Multiple Sclerosis
Part of paid clinical trials in New York, New York.
- Sponsor
- Hunter College of City University of New York
- Study ID
- NCT06506929
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- Task specific physical therapy — OTHERPhysical Therapy based specifically on tasks that the participant os having difficulty with
Study Details
The purpose of this study is to find effective physical therapy treatments for individuals who have severe multiple sclerosis. Physical therapy treatments for mild-to-moderate multiple sclerosis exists, however, very limited research has been done for physical therapy for severe multiple sclerosis (MS). In this study 10 participants diagnosed with severe MS will engage in 1-hour physical therapy sessions twice a week for 6 weeks to address limitations in standing, balancing, and bed mobility.
Key Dates
- Start date
- Jul 10, 2024
- Status verified
- Jul 2024
- Primary completion
- Dec 31, 2025
- Completion
- Jan 31, 2026
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Task specific Physical TherapyParticipants will received task specific physical therapy for 1 hour, twice a week for 6 weeks
Primary Outcome Measure
Multiple Sclerosis Physical Frailty Functional Assessment (MSPFFA) [ Time Frame: Will be administered twice, once at pre-intervention and once at post-intervention. The length of the intervention is 6 weeks. ]
Central Contacts
- Herbert Karpatkin, DSc212-396-7115
- Arita Winter212-650-3053
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Hunter College, Physical Therapy Department, City University of New York | New York | New York | 10010 |
Find similar trials in New York, NY
Related Studies
- Genes and Environment in Multiple SclerosisRecruiting · Columbia University · Bethesda, Maryland
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPHASE4 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · New Haven, Connecticut
- Vancomycin Study in Multiple Sclerosis (MS)PHASE1 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York